Biopharma and medtech venture investments trend up in Q1

Biopharma and medtech venture investments trend up in Q1

Venture investment in biopharma and medtech has remained strong through the first quarter of 2024, as detailed in J.P. Morgan’s latest report, which utilizes data compiled by DealForma. Download the reports

DealForma Research

Explore More
Autoimmune R&D Partnerships, M&A, Ventures, and IPOs by TA - Q2 to QTD Q4 2024 Review

Autoimmune R&D Partnerships, M&A, Ventures, and IPOs by TA – Q2 to QTD Q4 2024 Review

MedTech, Device, Digital Health, Wearables – M&A, Ventures and IPOs in Q3 2024

MedTech, Device, Digital Health, Wearables – M&A, Ventures and IPOs in Q3 2024

Biopharma Therapeutics and Platforms IPO Activity - Q3 2024

Biopharma Therapeutics and Platforms IPO Activity – Q3 2024

All of this by stage, disease indication, modality, target…

Schedule your Demo
+ 0 k
Licensing Deals
+ 0 k
M&A
+ 0 k
Other Deals
+ 0 k
Funding Rounds
+ 0 k
Company Profiles
+ 0 k
Drug Sales Figures
DealForma Logo

DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.

Linkedin

Database

Company

Comparisons

Website Design by Once Interactive